ALZAMEND NEURO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ALZAMEND NEURO, INC. (ALZN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.59 million shares for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-22.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-07-22
- ALZAMEND NEURO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-04-30 was 0.00 shares, a 100.00% decline year-over-year.
- ALZAMEND NEURO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-04-30 was 200.00K shares.
- ALZAMEND NEURO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-01-31 was 0.00 shares.
- ALZAMEND NEURO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-10-31 was 250.00K shares.
- ALZAMEND NEURO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2026 was 1.59M shares.
- ALZAMEND NEURO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.00M shares, a 2.56% increase from fiscal 2022.
- ALZAMEND NEURO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.95M shares, a 1460.00% increase from fiscal 2021.
- ALZAMEND NEURO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 125.00K shares, a 96.67% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-04-30 | 1.59M shares 10-K · filed 2026-07-22 | |||
| 2023-04-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-27 | 2.00M shares 10-K · filed 2023-07-27 | ||
| 2023-01-31 | 2.00M shares 10-Q · filed 2023-03-15 | |||
| 2022-04-30 | 200.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-19 | 200.00K shares derived: sum of 2 quarters · filed 2022-07-19 | 450.00K shares derived: sum of 3 quarters · filed 2022-07-19 | 1.95M shares 10-K · filed 2022-07-19 |
| 2022-01-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-03-15 | 250.00K shares derived: sum of 2 quarters · filed 2022-03-15 | 1.75M shares 10-Q · filed 2022-03-15 | |
| 2021-10-31 | 250.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-12-13 | 1.75M shares 10-Q · filed 2021-12-13 | ||
| 2021-07-31 | 1.50M shares 10-Q · filed 2021-09-13 | |||
| 2021-04-30 | 125.00K shares 10-K · filed 2022-07-19 | |||
| 2020-04-30 | 3.75M shares 10-K · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |